{"id":1121,"date":"2026-02-09T11:54:19","date_gmt":"2026-02-09T02:54:19","guid":{"rendered":"https:\/\/bitpress.kr\/?p=1121"},"modified":"2026-02-09T12:10:15","modified_gmt":"2026-02-09T03:10:15","slug":"domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis","status":"publish","type":"post","link":"https:\/\/bitpress.kr\/en\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/","title":{"rendered":"Korea\u2019s GLP-1 diet drug war: the top 5 contenders racing to \u201ccatch Wegovy\u201d"},"content":{"rendered":"

K-bio\u2019s ambition to tap a KRW 100 trillion global market: who is the real alternative?<\/strong><\/p>\n\n\n\n

\n\n\n\n

Market size: Korea\u2019s GLP-1 market takes off in 2025<\/strong><\/h2>\n\n\n\n

The global market for GLP-1 obesity drugs is expected to grow explosively, at 17.5% a year, from about KRW 74 trillion in 2024 to KRW 217 trillion by 2030<\/strong>. The Korean market is also expanding rapidly: Novo Nordisk\u2019s Wegovy, the overseas front-runner, launched in 2024 and topped KRW 200 billion in cumulative sales within three quarters, taking a 66% market share.<\/p>\n\n\n\n

In 2025, outpatient prescriptions in Korea\u2019s diabetes drug market rose 3.9% to KRW 1.5463 trillion. Among them, the GLP-1 injectables Trulicity from Lilly Korea and Xultophy FlexTouch from Novo Nordisk grew strongly, by 44.9% and 57.7% respectively. However, the lack of a homegrown new drug<\/strong>is still considered a sore spot for Korea\u2019s pharmaceutical industry.<\/p>\n\n\n\n

\n\n\n\n

Top 5 contenders: where each stands in clinical development<\/strong><\/h2>\n\n\n\n

1. Hanmi Pharmaceutical (128940): launch of \u201cKorea\u2019s first homegrown obesity drug\u201d is imminent<\/strong><\/h3>\n\n\n\n

Current share price:<\/strong> KRW 541,000 (as of Feb. 5)
Brokerage price targets:<\/strong> Consensus of KRW 560,000 (Samsung Securities) and KRW 570,000 (Meritz Securities)
Clinical progress:<\/strong> Efpeglenatide Phase 3 completed in Korea<\/strong>; targeting launch in the second half of 2026<\/p>\n\n\n\n

Hanmi Pharmaceutical is the only Korean GLP-1 developer to have reached the marketing approval application stage<\/strong>. In October 2025, efpeglenatide\u2019s Phase 3 trial demonstrated weight loss and superior safety (a double-digit percentage reduction in gastrointestinal side effects). In particular, with a pricing strategy 30\u201340% below Wegovy and Mounjaro<\/strong>, the company aims to reach KRW 100 billion in sales within a year of launch.<\/p>\n\n\n\n

Feasibility:<\/strong> \u25b2\u25b2\u25b2\u25b2\u25b2 (5\/5)
It has already completed Phase 3 and secured stable production capacity through its Pyeongtaek smart plant. A domestic launch in the second half of 2026 looks all but certain, and the title of Korea\u2019s first GLP-1 obesity drug<\/strong>should give it a first-mover advantage.<\/p>\n\n\n\n

\n\n\n\n

2. Peptron (087010): a \u201conce-a-month injection\u201d collaboration with Eli Lilly<\/strong><\/h3>\n\n\n\n

Current share price:<\/strong> KRW 247,500 (as of Feb. 6)
Expert price targets:<\/strong> KRW 300,000 (Kim Min-sung), KRW 350,000 (Kim Young-min)
Clinical progress:<\/strong>Joint research agreement with Eli Lilly extended<\/strong> (December 2025, expanded to 24 months)<\/p>\n\n\n\n

Peptron is developing long-acting injectables with its in-house \u201cSmartDepot\u201d<\/strong> platform technology. In December 2025, it extended its joint research with Eli Lilly from 14 months to 24 months, taking technology validation a step further. Beyond extending Mounjaro\u2019s half-life, it is also researching a long-acting formulation of a next-generation muscle-building compound (UCN2)<\/strong>.<\/p>\n\n\n\n

Feasibility:<\/strong> \u25b2\u25b2\u25b2\u25b2\u25b3 (4\/5)
The chances of a full contract with Eli Lilly are rising, but the non-exclusive deal structure<\/strong>is a variable. The outline of a concrete technology export (licensing-out) deal is expected to emerge at the J.P. Morgan Healthcare Conference in January 2026.<\/p>\n\n\n\n

\n\n\n\n

3. Inventage Lab (389470): a \u201csecond joint study\u201d with Boehringer Ingelheim<\/strong><\/h3>\n\n\n\n

Current share price:<\/strong> KRW 68,300 (as of Feb. 6)
Expert price targets:<\/strong> KRW 100,000 (Kim Young-min, Choi Won-beom), KRW 110,000 (Seong Ha-jun)
Clinical progress:<\/strong> With Boehringer Ingelheim, a second joint research agreement<\/strong> (November 2025)<\/p>\n\n\n\n

Inventage Lab ‘IVL-DrugFluidic’<\/strong> develops long-acting injectables using microfluidic technology. Following its first agreement in September 2024, in November 2025 it signed a joint research agreement on a second peptide compound<\/strong>, demonstrating that its platform technology can scale. It has also signed licensing-out deals with Korean drugmakers such as Daewoong Pharmaceutical and Chong Kun Dang.<\/p>\n\n\n\n

Feasibility:<\/strong> \u25b2\u25b2\u25b2\u25b3\u25b3 (3\/5)
Its collaboration with Boehringer Ingelheim could move beyond platform validation to a large-scale technology transfer<\/strong>, but it has not yet become a full contract. Pharmacokinetic study results in the first half of 2026 are likely to be a key turning point.<\/p>\n\n\n\n

\n\n\n\n

4. G2GBIO (456160): \u201cthree-month long-acting\u201d semaglutide<\/strong><\/h3>\n\n\n\n

Current share price:<\/strong> KRW 79,700 (as of Feb. 6)
Brokerage price targets:<\/strong> KRW 319,800 (SMIC, Base Case 1)
Clinical progress:<\/strong>One-month long-acting semaglutide-based formulation<\/strong> preparing to enter clinical trials (targeting the first half of 2026)<\/p>\n\n\n\n

G2GBIO is developing one-month and three-month long-acting formulations with its \u201cInnoLAMP\u201d<\/strong> microsphere technology. At the PODD conference in October 2025, it unveiled pharmacokinetic results for its three-month semaglutide formulation for the first time, demonstrating its technology. It has signed joint development agreements with three global drugmakers, including Boehringer Ingelheim.<\/p>\n\n\n\n

Feasibility:<\/strong> \u25b2\u25b2\u25b2\u25b3\u25b3 (3\/5)
With the semaglutide patent expiring (2026)<\/strong>, its strategy of targeting the global generics market is sound, but it has not yet entered Phase 1, so clinical risk<\/strong>remains. A strength is that it has already built mass-production capacity and can absorb global CDMO demand.<\/p>\n\n\n\n

\n\n\n\n

5. Ildong Pharmaceutical (249420): taking on an \u201coral (pill) obesity drug\u201d<\/strong><\/h3>\n\n\n\n

Current share price:<\/strong> KRW 36,500 (as of Feb. 9)
Brokerage price targets:<\/strong> KRW 45,000 (SK Securities)
Clinical progress:<\/strong>ID110521156 Phase 1 completed<\/strong>; preparing for global Phase 2<\/p>\n\n\n\n

Ildong Pharmaceutical\u2019s subsidiary Yunovia is developing the oral small-molecule GLP-1 receptor agonist<\/strong> ID110521156. In a Phase 1 trial in September 2025, it achieved up to 13.8% weight loss<\/strong>after four weeks of dosing, ranking among the best results for oral candidates. It overcame the structural weaknesses of Pfizer\u2019s danuglipron class, with 54% bioavailability and no link to liver toxicity.<\/p>\n\n\n\n

Feasibility:<\/strong> \u25b2\u25b2\u25b2\u25b3\u25b3 (3\/5)
Oral delivery<\/strong>offers convenience and is a powerful differentiator, but it is still in Phase 1 and needs to enter global Phase 2 and negotiate a technology transfer (licensing-out). At BIO-Europe in November 2025, it held partnering meetings with global drugmakers, stepping up talks on a technology export.<\/p>\n\n\n\n

\n\n\n\n

How big a deal is this?<\/strong><\/h2>\n\n\n\n

\u201cA KRW 217 trillion market growing 17.5% a year through 2030\u201d<\/strong><\/p>\n\n\n\n

The GLP-1 market is expanding beyond simple obesity treatment into diabetes, MASH (metabolic dysfunction-associated steatohepatitis), cardiovascular disease and dementia<\/strong>: a megatrend<\/strong>. In particular, formulation innovation<\/strong>(long-acting and oral) is the key driver of market growth, and Korean companies are targeting this niche.<\/p>\n\n\n\n

Hanmi Pharmaceutical aims to take the market first with its title of Korea\u2019s first homegrown drug<\/strong>; Peptron, Inventage Lab and G2GBIO are seeking technology validation through collaborations with global Big Pharma<\/strong>; and Ildong Pharmaceutical is aiming for Oral delivery<\/strong>as a game changer to reshape the market.<\/p>\n\n\n\n

Brokerages have set price targets of KRW 560,000 for Hanmi Pharmaceutical, KRW 300,000 or more for Peptron and KRW 100,000 or more for Inventage Lab<\/strong>, betting on these companies\u2019 growth.<\/p>\n\n\n\n

\n\n\n\n

Investment points at a glance<\/strong><\/h2>\n\n\n\n
Company<\/th>Key momentum<\/th>Risks<\/th><\/tr><\/thead>
Hanmi Pharmaceutical<\/strong><\/td>Domestic launch confirmed for the second half of 2026; KRW 100 billion sales target<\/td>Shift in partner MSD\u2019s MASH treatment strategy<\/td><\/tr>
Peptron<\/strong><\/td>Hopes for a full Eli Lilly contract; announcement at JPMHC 2026<\/td>Non-exclusive deal; possible delays in technology validation<\/td><\/tr>
Inventage Lab<\/strong><\/td>Second Boehringer Ingelheim agreement; platform technology validation<\/td>Still early in clinical development; revenue generation uncertain<\/td><\/tr>
G2GBIO<\/strong><\/td>Three-month long-acting technology; benefits from semaglutide patent expiry<\/td>Not yet in clinical trials; uncertainty over commercialization<\/td><\/tr>
Ildong Pharmaceutical<\/strong><\/td>Convenience of an oral drug; 13.8% weight loss<\/td>Only Phase 1 completed; global Phase 2 needed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\u203b This article is for investment reference only. Investors bear final responsibility for their investment decisions.<\/p>\n\n\n\n

\n\n\n\n

BITPRESS Insight<\/strong><\/h2>\n\n\n\n

\u201cHanmi Pharmaceutical leads alone through 2026; after that, it\u2019s a war of platform technologies\u201d<\/strong><\/p>\n\n\n\n

Korea\u2019s GLP-1 market is confirming the truth that \u201cwhat matters is not coming out fast, but coming out right\u201d<\/strong>. Now that Hanmi Pharmaceutical is the only one to have finished Phase 3 and is about to launch, the other four companies are trying to stand out with formulation innovation<\/strong>.<\/p>\n\n\n\n

There are two key takeaways.<\/strong> First, Collaboration with global Big Pharma has become the ultimate rite of passage for technology validation<\/strong>. The fact that Peptron (Eli Lilly), Inventage Lab (Boehringer Ingelheim) and G2GBIO (three companies including Boehringer Ingelheim) are all conducting joint research with global drugmakers shows that the world recognizes the maturity of Korean technology. Second, a showdown between oral and long-acting drugs<\/strong>is expected to heat up. Ildong Pharmaceutical\u2019s oral drug, with 13.8% weight loss, is a variable that could shake the advantages of injectables.<\/p>\n\n\n\n

When investors should pay attention:<\/strong> \u2460 The J.P. Morgan Healthcare Conference in January 2026<\/strong>, where the outline of Peptron\u2019s technology export may emerge; \u2461 First half of 2026<\/strong> G2GBIO\u2019s entry into clinical trials; \u2462 Second half of 2026<\/strong> Hanmi Pharmaceutical\u2019s actual market share after launch. Hanmi Pharmaceutical will likely take the Korean market first, but in the global market the winner will be decided by the formulation battle of \u201cone month vs. three months vs. oral\u201d<\/strong>.<\/p>\n\n\n\n

Conclusion:<\/strong> For now, we are at the stage of valuations driven by expectations<\/strong> . Real proof of earnings begins in 2026.<\/p>\n\n\n\n

\n\n\n\n

Sources (links)
https:\/\/stock.mk.co.kr\/price\/home\/KR7128940004<\/a>
https:\/\/bbn.kiwoom.com\/rfCR11822<\/a>
https:\/\/comp.hankyung.com\/apps\/stock-analysis\/analysis\/consensus?no=001230<\/a>
https:\/\/www.mk.co.kr\/news\/stock\/11957403<\/a>
https:\/\/files-scs.pstatic.net\/2026\/01\/05\/66WqT2xNds\/260105.pdf<\/a>
https:\/\/stock.mk.co.kr\/price\/home\/KR7195940002<\/a>
https:\/\/stock11.mk.co.kr\/price\/chart\/KR7000250001<\/a>
https:\/\/marketin.edaily.co.kr\/News\/ReadE?newsId=02994646645320672<\/a>
https:\/\/www.docdocdoc.co.kr\/news\/articleView.html?idxno=3027800<\/a>
https:\/\/koreajoongangdaily.joins.com\/news\/2024-10-13\/business\/industry\/Korean-drugmakers-race-to-enter-booming-weight-loss-drug-market\/2153241<\/a>
https:\/\/www.grandviewresearch.com\/horizon\/outlook\/south-korea-obesity-drugs-market-size-forecast-report<\/a><\/p>","protected":false},"excerpt":{"rendered":"

\uae00\ub85c\ubc8c 100\uc870 \uc2dc\uc7a5 \ub178\ub9ac\ub294 K-\ubc14\uc774\uc624\uc758 \uc57c\ub9dd, \ub204\uac00 \uc9c4\uc9dc \ub300\uc548\uc778\uac00 \uc2dc\uc7a5 \uaddc\ubaa8: 2025\ub144 \uad6d\ub0b4 GLP-1 \uc2dc\uc7a5 \ubcf8\uaca9 \uac1c\ud654 \uae00\ub85c\ubc8c GLP-1 \uacc4\uc5f4 \ube44\ub9cc \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2024\ub144 \uc57d 74\uc870\uc6d0\uc5d0\uc11c 2030\ub144 217\uc870\uc6d0\uae4c\uc9c0 \uc5f0\ud3c9\uade0 17.5%\uc758 \ud3ed\ubc1c\uc801 \uc131\uc7a5\uc774 \uc608\uc0c1\ub41c\ub2e4. \uad6d\ub0b4 \uc2dc\uc7a5 \uc5ed\uc2dc \ud574\uc678 \uc120\ub450\uc8fc\uc790\uc778 \ub178\ubcf4\ub178\ub514\uc2a4\ud06c ‘\uc704\uace0\ube44’\uac00 2024\ub144 \ucd9c\uc2dc \ud6c4 3\ubd84\uae30 \ub9cc\uc5d0 \ub204\uc801 \ub9e4\ucd9c 2,000\uc5b5\uc6d0\uc744 \ub3cc\ud30c\ud558\uba70 \uc810\uc720\uc728 66%\ub97c \ucc28\uc9c0\ud558\ub294 \ub4f1 \uae09\uc18d\ub3c4\ub85c \ud655\ub300\ub418\uace0 […]<\/p>\n","protected":false},"author":1,"featured_media":1125,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"bitpress_en_title":"","bitpress_en_desc":"","footnotes":""},"categories":[24,223],"tags":[483,492,478,482,487,490,479,493,481,484,489,488,491,486,485,480],"class_list":["post-1121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-it-business","category-korea-stocks","tag-glp-1","tag-k-","tag-478","tag-482","tag-487","tag-490","tag-479","tag-493","tag-481","tag-484","tag-489","tag-488","tag-491","tag-486","tag-485","tag-480"],"acf":[],"yoast_head":"\n\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: "\uc704\uace0\ube44 \uc7a1\uc544\ub77c" \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d - BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bitpress.kr\/en\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: "\uc704\uace0\ube44 \uc7a1\uc544\ub77c" \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d - BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4\" \/>\n<meta property=\"og:description\" content=\"\uae00\ub85c\ubc8c 100\uc870 \uc2dc\uc7a5 \ub178\ub9ac\ub294 K-\ubc14\uc774\uc624\uc758 \uc57c\ub9dd, \ub204\uac00 \uc9c4\uc9dc \ub300\uc548\uc778\uac00 \uc2dc\uc7a5 \uaddc\ubaa8: 2025\ub144 \uad6d\ub0b4 GLP-1 \uc2dc\uc7a5 \ubcf8\uaca9 \uac1c\ud654 \uae00\ub85c\ubc8c GLP-1 \uacc4\uc5f4 \ube44\ub9cc \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2024\ub144 \uc57d 74\uc870\uc6d0\uc5d0\uc11c 2030\ub144 217\uc870\uc6d0\uae4c\uc9c0 \uc5f0\ud3c9\uade0 17.5%\uc758 \ud3ed\ubc1c\uc801 \uc131\uc7a5\uc774 \uc608\uc0c1\ub41c\ub2e4. \uad6d\ub0b4 \uc2dc\uc7a5 \uc5ed\uc2dc \ud574\uc678 \uc120\ub450\uc8fc\uc790\uc778 \ub178\ubcf4\ub178\ub514\uc2a4\ud06c ‘\uc704\uace0\ube44’\uac00 2024\ub144 \ucd9c\uc2dc \ud6c4 3\ubd84\uae30 \ub9cc\uc5d0 \ub204\uc801 \ub9e4\ucd9c 2,000\uc5b5\uc6d0\uc744 \ub3cc\ud30c\ud558\uba70 \uc810\uc720\uc728 66%\ub97c \ucc28\uc9c0\ud558\ub294 \ub4f1 \uae09\uc18d\ub3c4\ub85c \ud655\ub300\ub418\uace0 […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bitpress.kr\/en\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T02:54:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T03:10:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bitpress.kr\/wp-content\/uploads\/2026\/02\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1271\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"bp_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"bp_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/\"},\"author\":{\"name\":\"bp_admin\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#\\\/schema\\\/person\\\/6f9dfc288964a001cd1b5d21e7dc099a\"},\"headline\":\"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: “\uc704\uace0\ube44 \uc7a1\uc544\ub77c” \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d\",\"datePublished\":\"2026-02-09T02:54:19+00:00\",\"dateModified\":\"2026-02-09T03:10:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/\"},\"wordCount\":146,\"publisher\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bitpress.kr\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp\",\"keywords\":[\"GLP-1\",\"K-\ubc14\uc774\uc624\",\"\uad6d\ub0b4 \ubc14\uc774\uc624\",\"\ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d\",\"\ub2f9\ub1e8\ubcd1 \uce58\ub8cc\",\"\ub300\uc0ac\uc131 \uc9c8\ud658\",\"\ube44\ub9cc \uce58\ub8cc\uc81c\",\"\uc2e0\uc57d \uac1c\ubc1c\",\"\uc704\uace0\ube44 \ub300\ud56d\ub9c8\",\"\uc778\ubca4\ud2f0\uc9c0\ub7a9\",\"\uc77c\ub3d9\uc81c\uc57d\",\"\uc784\uc0c1 \uc2dc\ud5d8\",\"\uc81c\uc57d \uc0b0\uc5c5\",\"\uc9c0\ud22c\uc9c0\ubc14\uc774\uc624\",\"\ud3a9\ud2b8\ub860\",\"\ud55c\ubbf8\uc57d\ud488\"],\"articleSection\":[\"IT\\\/\ube44\uc988\ub2c8\uc2a4\",\"\uad6d\ub0b4 \uc8fc\uc2dd\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/\",\"url\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/\",\"name\":\"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: \\\"\uc704\uace0\ube44 \uc7a1\uc544\ub77c\\\" \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d - BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bitpress.kr\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp\",\"datePublished\":\"2026-02-09T02:54:19+00:00\",\"dateModified\":\"2026-02-09T03:10:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/bitpress.kr\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp\",\"contentUrl\":\"https:\\\/\\\/bitpress.kr\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp\",\"width\":1024,\"height\":1271},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/bitpress.kr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: “\uc704\uace0\ube44 \uc7a1\uc544\ub77c” \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#website\",\"url\":\"https:\\\/\\\/bitpress.kr\\\/\",\"name\":\"BitPress : \ube44\ud2b8\ud504\ub808\uc2a4\",\"description\":\"\ube44\ud2b8\ucf54\uc778\u00b7\uac00\uc0c1\ud654\ud3d0\u00b7\ucf54\uc778\ubd80\ud130 \uad6d\ub0b4\uc678 \uc8fc\uc2dd\uae4c\uc9c0, \uc8fc\uc694 \ub274\uc2a4\uc640 \uc774\uc288\uc758 \ud750\ub984\uc744 \uc815\ub9ac\ud569\ub2c8\ub2e4.\",\"publisher\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bitpress.kr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#organization\",\"name\":\"BitPress : \ube44\ud2b8\ud504\ub808\uc2a4\",\"url\":\"https:\\\/\\\/bitpress.kr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/bitpress.kr\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/bitpress_fb_og.webp\",\"contentUrl\":\"https:\\\/\\\/bitpress.kr\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/bitpress_fb_og.webp\",\"width\":1200,\"height\":630,\"caption\":\"BitPress : \ube44\ud2b8\ud504\ub808\uc2a4\"},\"image\":{\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bitpress.kr\\\/#\\\/schema\\\/person\\\/6f9dfc288964a001cd1b5d21e7dc099a\",\"name\":\"bp_admin\",\"url\":\"https:\\\/\\\/bitpress.kr\\\/en\\\/author\\\/bp_admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: \"\uc704\uace0\ube44 \uc7a1\uc544\ub77c\" \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d - BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bitpress.kr\/en\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/","og_locale":"en_US","og_type":"article","og_title":"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: \"\uc704\uace0\ube44 \uc7a1\uc544\ub77c\" \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d - BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4","og_description":"\uae00\ub85c\ubc8c 100\uc870 \uc2dc\uc7a5 \ub178\ub9ac\ub294 K-\ubc14\uc774\uc624\uc758 \uc57c\ub9dd, \ub204\uac00 \uc9c4\uc9dc \ub300\uc548\uc778\uac00 \uc2dc\uc7a5 \uaddc\ubaa8: 2025\ub144 \uad6d\ub0b4 GLP-1 \uc2dc\uc7a5 \ubcf8\uaca9 \uac1c\ud654 \uae00\ub85c\ubc8c GLP-1 \uacc4\uc5f4 \ube44\ub9cc \uce58\ub8cc\uc81c \uc2dc\uc7a5\uc740 2024\ub144 \uc57d 74\uc870\uc6d0\uc5d0\uc11c 2030\ub144 217\uc870\uc6d0\uae4c\uc9c0 \uc5f0\ud3c9\uade0 17.5%\uc758 \ud3ed\ubc1c\uc801 \uc131\uc7a5\uc774 \uc608\uc0c1\ub41c\ub2e4. \uad6d\ub0b4 \uc2dc\uc7a5 \uc5ed\uc2dc \ud574\uc678 \uc120\ub450\uc8fc\uc790\uc778 \ub178\ubcf4\ub178\ub514\uc2a4\ud06c ‘\uc704\uace0\ube44’\uac00 2024\ub144 \ucd9c\uc2dc \ud6c4 3\ubd84\uae30 \ub9cc\uc5d0 \ub204\uc801 \ub9e4\ucd9c 2,000\uc5b5\uc6d0\uc744 \ub3cc\ud30c\ud558\uba70 \uc810\uc720\uc728 66%\ub97c \ucc28\uc9c0\ud558\ub294 \ub4f1 \uae09\uc18d\ub3c4\ub85c \ud655\ub300\ub418\uace0 […]","og_url":"https:\/\/bitpress.kr\/en\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/","og_site_name":"BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4","article_published_time":"2026-02-09T02:54:19+00:00","article_modified_time":"2026-02-09T03:10:15+00:00","og_image":[{"width":1024,"height":1271,"url":"https:\/\/bitpress.kr\/wp-content\/uploads\/2026\/02\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp","type":"image\/jpeg"}],"author":"bp_admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"bp_admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/#article","isPartOf":{"@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/"},"author":{"name":"bp_admin","@id":"https:\/\/bitpress.kr\/#\/schema\/person\/6f9dfc288964a001cd1b5d21e7dc099a"},"headline":"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: “\uc704\uace0\ube44 \uc7a1\uc544\ub77c” \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d","datePublished":"2026-02-09T02:54:19+00:00","dateModified":"2026-02-09T03:10:15+00:00","mainEntityOfPage":{"@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/"},"wordCount":146,"publisher":{"@id":"https:\/\/bitpress.kr\/#organization"},"image":{"@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/bitpress.kr\/wp-content\/uploads\/2026\/02\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp","keywords":["GLP-1","K-\ubc14\uc774\uc624","\uad6d\ub0b4 \ubc14\uc774\uc624","\ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d","\ub2f9\ub1e8\ubcd1 \uce58\ub8cc","\ub300\uc0ac\uc131 \uc9c8\ud658","\ube44\ub9cc \uce58\ub8cc\uc81c","\uc2e0\uc57d \uac1c\ubc1c","\uc704\uace0\ube44 \ub300\ud56d\ub9c8","\uc778\ubca4\ud2f0\uc9c0\ub7a9","\uc77c\ub3d9\uc81c\uc57d","\uc784\uc0c1 \uc2dc\ud5d8","\uc81c\uc57d \uc0b0\uc5c5","\uc9c0\ud22c\uc9c0\ubc14\uc774\uc624","\ud3a9\ud2b8\ub860","\ud55c\ubbf8\uc57d\ud488"],"articleSection":["IT\/\ube44\uc988\ub2c8\uc2a4","\uad6d\ub0b4 \uc8fc\uc2dd"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/","url":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/","name":"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: \"\uc704\uace0\ube44 \uc7a1\uc544\ub77c\" \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d - BITPRESS : \ube44\ud2b8\ud504\ub808\uc2a4 - \ud22c\uc790\u00b7\ucf54\uc778\u00b7\uc8fc\uc2dd \uc2dc\uc7a5\uc744 \uc77d\ub294 \ub274\uc2a4","isPartOf":{"@id":"https:\/\/bitpress.kr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/#primaryimage"},"image":{"@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/bitpress.kr\/wp-content\/uploads\/2026\/02\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp","datePublished":"2026-02-09T02:54:19+00:00","dateModified":"2026-02-09T03:10:15+00:00","breadcrumb":{"@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/#primaryimage","url":"https:\/\/bitpress.kr\/wp-content\/uploads\/2026\/02\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp","contentUrl":"https:\/\/bitpress.kr\/wp-content\/uploads\/2026\/02\/bitpress_domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis.webp","width":1024,"height":1271},{"@type":"BreadcrumbList","@id":"https:\/\/bitpress.kr\/domestic-glp1-obesity-drug-war-top-5-bio-companies-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bitpress.kr\/"},{"@type":"ListItem","position":2,"name":"\uad6d\ub0b4 GLP-1 \ub2e4\uc774\uc5b4\ud2b8 \uc2e0\uc57d \uc804\uc7c1: “\uc704\uace0\ube44 \uc7a1\uc544\ub77c” \uc120\ub450\uc8fc\uc790 TOP5 \ubd84\uc11d"}]},{"@type":"WebSite","@id":"https:\/\/bitpress.kr\/#website","url":"https:\/\/bitpress.kr\/","name":"BitPress : \ube44\ud2b8\ud504\ub808\uc2a4","description":"\ube44\ud2b8\ucf54\uc778\u00b7\uac00\uc0c1\ud654\ud3d0\u00b7\ucf54\uc778\ubd80\ud130 \uad6d\ub0b4\uc678 \uc8fc\uc2dd\uae4c\uc9c0, \uc8fc\uc694 \ub274\uc2a4\uc640 \uc774\uc288\uc758 \ud750\ub984\uc744 \uc815\ub9ac\ud569\ub2c8\ub2e4.","publisher":{"@id":"https:\/\/bitpress.kr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bitpress.kr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/bitpress.kr\/#organization","name":"BitPress : \ube44\ud2b8\ud504\ub808\uc2a4","url":"https:\/\/bitpress.kr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bitpress.kr\/#\/schema\/logo\/image\/","url":"https:\/\/bitpress.kr\/wp-content\/uploads\/2025\/12\/bitpress_fb_og.webp","contentUrl":"https:\/\/bitpress.kr\/wp-content\/uploads\/2025\/12\/bitpress_fb_og.webp","width":1200,"height":630,"caption":"BitPress : \ube44\ud2b8\ud504\ub808\uc2a4"},"image":{"@id":"https:\/\/bitpress.kr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/bitpress.kr\/#\/schema\/person\/6f9dfc288964a001cd1b5d21e7dc099a","name":"bp_admin","url":"https:\/\/bitpress.kr\/en\/author\/bp_admin\/"}]}},"_links":{"self":[{"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/posts\/1121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/comments?post=1121"}],"version-history":[{"count":2,"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/posts\/1121\/revisions"}],"predecessor-version":[{"id":1124,"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/posts\/1121\/revisions\/1124"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/media\/1125"}],"wp:attachment":[{"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/media?parent=1121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/categories?post=1121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bitpress.kr\/en\/wp-json\/wp\/v2\/tags?post=1121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}